Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Up 8.7% in January

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 9,110,000 shares, an increase of 8.7% from the January 15th total of 8,380,000 shares. Based on an average daily trading volume, of 1,710,000 shares, the days-to-cover ratio is currently 5.3 days.

Institutional Trading of Autolus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of AUTL. Hennion & Walsh Asset Management Inc. purchased a new stake in shares of Autolus Therapeutics during the 4th quarter worth $611,000. Wellington Management Group LLP lifted its position in shares of Autolus Therapeutics by 35.4% during the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company's stock valued at $87,919,000 after buying an additional 6,330,392 shares during the last quarter. FMR LLC boosted its holdings in shares of Autolus Therapeutics by 44.6% in the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company's stock valued at $64,519,000 after buying an additional 5,478,706 shares in the last quarter. Erste Asset Management GmbH bought a new position in shares of Autolus Therapeutics during the 3rd quarter worth approximately $708,000. Finally, GSA Capital Partners LLP bought a new position in shares of Autolus Therapeutics during the 3rd quarter worth approximately $1,082,000. Institutional investors own 72.83% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on AUTL shares. The Goldman Sachs Group upgraded Autolus Therapeutics from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $7.00 to $7.60 in a report on Monday, November 18th. Redburn Atlantic raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price for the company in a research note on Friday, November 15th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Autolus Therapeutics has an average rating of "Buy" and a consensus target price of $10.40.

Autolus Therapeutics Stock Performance

Autolus Therapeutics stock traded down $0.05 during midday trading on Thursday, hitting $1.95. 739,070 shares of the company's stock were exchanged, compared to its average volume of 1,138,260. The company has a market cap of $518.88 million, a PE ratio of -1.61 and a beta of 2.02. The firm has a 50-day moving average of $2.25 and a two-hundred day moving average of $3.22. Autolus Therapeutics has a 12 month low of $1.87 and a 12 month high of $6.70.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.